Spinal Cord Injury
A spinal cord injury disrupts brain-to-body communication, impairing motor and sensory function.
nervgen.comCrawled Nov 19, 2026
A spinal cord injury disrupts brain-to-body communication, impairing motor and sensory function.
NervGen’s lead compound, NVG-291, is in clinical development for the treatment of chronic tetraplegia, the leading form of spinal cord injury.
The page explains the science behind NervGen’s work on spinal cord injury and nervous system repair using NVG-291.
The page discusses how caregiving involves managing physical needs and engaging individuals to stimulate mental activity.
Steph Jagger’s mother’s diagnosis with Alzheimer’s disease inspired her to seek ways to spend time with her.
NVG-291 showed statistically significant improvement in gait quality for 100% of subjects in a study assessing neural recovery.
NervGen announced the pricing of an underwritten public offering of 24,000,000 common shares and warrants for spinal cord injury treatments.
NervGen’s Base Shelf Prospectus and Prospectus Supplement are accessible through SEDAR+.
NervGen completed an FDA End-of-Phase 2 meeting for the RESTORE study of NVG-291 in chronic tetraplegia, with site activation underway.
NervGen appointed Keith Vendola, MD, MBA, as Chief Financial Officer.
NervGen’s executive team, including Adam Rogers, MD, participated in a public announcement about the company’s progress.
The company’s leadership team has experience and a track record of success in executing its mission.
Explore NervGen corporate governance, leadership structure, and oversight of NVG-291 development programs.
The company aims to transform the lives of individuals living with spinal cord injury.
Contact NervGen for inquiries about NVG-291, spinal cord injury research and investor relations.
NervGen is advancing NVG-291 to enable the nervous system to repair itself.
The company describes its clinical trials and invites participation in research.